Aibaidula Abudumijiti, Zhao Wang, Wu Jin-Song, Chen Hong, Shi Zhi-Feng, Zheng Lu-Lu, Mao Ying, Zhou Liang-Fu, Sui Guo-Dong
Glioma Surgery Division, Neurological Surgery Department, Huashan Hospital.
Department of Environmental Science and Engineering, Institute of Biomedical Sciences, and.
J Neurosurg. 2016 Jun;124(6):1611-8. doi: 10.3171/2015.4.JNS141833. Epub 2015 Nov 6.
OBJECT Conventional methods for isocitrate dehydrogenase 1 (IDH1) detection, such as DNA sequencing and immunohistochemistry, are time- and labor-consuming and cannot be applied for intraoperative analysis. To develop a new approach for rapid analysis of IDH1 mutation from tiny tumor samples, this study used microfluidics as a method for IDH1 mutation detection. METHODS Forty-seven glioma tumor samples were used; IDH1 mutation status was investigated by immunohistochemistry and DNA sequencing. The microfluidic device was fabricated from polydimethylsiloxane following standard soft lithography. The immunoanalysis was conducted in the microfluidic chip. Fluorescence images of the on-chip microcolumn taken by the charge-coupled device camera were collected as the analytical results readout. Fluorescence signals were analyzed by NIS-Elements software to gather detailed information about the IDH1 concentration in the tissue samples. RESULTS DNA sequencing identified IDH1 R132H mutation in 33 of 47 tumor samples. The fluorescence signal for IDH1-mutant samples was 5.49 ± 1.87 compared with 3.90 ± 1.33 for wild type (p = 0.005). Thus, microfluidics was capable of distinguishing IDH1-mutant tumor samples from wild-type samples. When the cutoff value was 4.11, the sensitivity of microfluidics was 87.9% and the specificity was 64.3%. CONCLUSIONS This new approach was capable of analyzing IDH1 mutation status of tiny tissue samples within 30 minutes using intraoperative microsampling. This approach might also be applied for rapid pathological diagnosis of diffuse gliomas, thus guiding personalized resection.
异柠檬酸脱氢酶1(IDH1)检测的传统方法,如DNA测序和免疫组织化学,耗时费力,无法用于术中分析。为开发一种从微小肿瘤样本中快速分析IDH1突变的新方法,本研究采用微流控技术作为IDH1突变检测方法。方法:使用47个胶质瘤肿瘤样本;通过免疫组织化学和DNA测序研究IDH1突变状态。微流控装置按照标准软光刻技术由聚二甲基硅氧烷制成。在微流控芯片中进行免疫分析。由电荷耦合器件相机拍摄的芯片上微柱的荧光图像作为分析结果读出。通过NIS-Elements软件分析荧光信号,以收集有关组织样本中IDH1浓度的详细信息。结果:DNA测序在47个肿瘤样本中的33个中鉴定出IDH1 R132H突变。IDH1突变样本的荧光信号为5.49±1.87,而野生型为3.90±1.33(p = 0.005)。因此,微流控技术能够区分IDH1突变肿瘤样本和野生型样本。当临界值为4.11时,微流控技术的灵敏度为87.9%,特异性为64.3%。结论:这种新方法能够在30分钟内使用术中微量采样分析微小组织样本的IDH1突变状态。这种方法也可能应用于弥漫性胶质瘤的快速病理诊断,从而指导个性化切除。